New Horizon’s Sales Surge as China Promotes Early Cancer Detection

Company’s first-mover advantage in at-home colorectal screening and China’s focus on early detection have turbocharged sales, though valuation remains frothy Key takeaways: New Horizon’s first-half revenues jumped more than fourfold, assisted by government early cancer testing drive Stock volatility could owe to frothy valuation, as well as unclear timeline for profitability By Richard Barbaroza New Horizon Health Ltd. (6606.HK), a Chinese maker of self-administered tests for colorectal cancer, has reported a more than fourfold increase in revenue in the first half of 2021, buoyed by the government’s recent campaign for…

Read MORE »